The ophthalmology pipeline of NovaBridge’s Visara subsidiary is led by VIS-101, a potential best-in-class dual VEGF‑A × ANG‑2 inhibitor in development for the treatment of retinal vascular diseases, such as wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO).
VIS-101
VIS-101 [Dual VEGF-A X ANG-2 Inhibitor]· Potential Best-in-Class for Retinal Vascular Diseases such as nAMD, DME and RVO · Potential Best-in-Class Durability
Mechanism of Action
Bispecific, Tetravalent design: increased binding sites and increased VEGF-A and ANG-2 affinity
- Humanized anti-VEGF-A mAb
~2X inhibitory activity - Optimized Fc region for shortened plasma half-life
- Anti-Ang-2 inhibitory peptides (18mers)
~17X inhibitory activity, for class leading durability
Selected Publications